Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule - 10 milligram(s) - proton pump inhibitors; omeprazole

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule - 20 milligram(s) - proton pump inhibitors; omeprazole

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - omeprazole - gastro-resistant capsule, hard - 40 milligram(s) - proton pump inhibitors; omeprazole

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 20 milligram(s) - proton pump inhibitors; pantoprazole

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - pantoprazole sodium sesquihydrate - gastro-resistant tablet - 40 milligram(s) - proton pump inhibitors; pantoprazole

Európska únia - angličtina - EMA (European Medicines Agency)

teva b.v.  - clopidogrel (as hydrochloride) - myocardial infarction; peripheral vascular diseases; stroke - antithrombotic agents - clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.adult patients suffering from acute coronary syndrome:non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillation in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Európska únia - angličtina - EMA (European Medicines Agency)

teva b.v. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drugs for treatment of bone diseases - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. treatment of paget’s disease of the bone in adults.,

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - budesonide - nebuliser suspension - 0.25 mg/2ml - glucocorticoids

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - budesonide - nebuliser suspension - 1 mg/2ml - glucocorticoids; budesonide

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - budesonide - nebuliser suspension - 0.5 mg/2ml - glucocorticoids; budesonide